TurboVax Inc, a C-corporation was founded on June 26, 2023 by Dr. Kishore R. Alugupalli, PhD, Associate Professor of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA, USA. Dr. Alugupalli currently is the full-time CEO of TurboVax Inc.

​

Vision. TurboVax Inc is interested in commercialization of an indispensable and path-breaking vaccine adjuvant named Turbo. Bacterial polysaccharide or glycoconjugate subunit vaccines when adjuvanted with Turbo induces long-lasting and highly protective immune responses across all ages and eliminates the need for boosters. By partnering with Vaccine developers, TurboVax Inc as the adjuvant developer and provider will help prevent a wide range of bacterial infections, decrease the threat of antimicrobial resistance, and minimize or eliminate the bacterial disease burden globally.

 

​

Innovation and Technology. TurboVax Inc’s innovation came directly from Dr. Alugupalli’s academic laboratory research of over 20 years, that was funded by the National Institutes of Health. Turbo as an adjuvant is superior to approved adjuvants such as alum. Unlike other adjuvants, Turbo promotes the induction of rapid, long-lasting, affinity-matured antibody responses of all IgG isotypes. Control of a given bacterial pathogen requires appropriate IgG isotypes. Therefore,  incorporation of Turbo to a vaccine will permit all possible IgG-mediated effector mechanisms required for protective immunity. Turbo adjuvanticity and its mechanism of action was rigorously tested in preclinical research studies with a range of monovalent and multivalent bacterial polysaccharide subunit vaccines currently approved by the US Food and Drug Administration (FDA) and/or prequalified by the World Health Organization (WHO).

 

Intellectual Property. Two provisional patents and a PCT have been filed on behalf Dr. Alugupalli as the sole Inventor by the Thomas Jefferson University. TurboVax Inc is the exclusive holder of the license on Turbo adjuvant technology and methods of use for Bacterial polysaccharide or glycoconjugate subunit vaccines.